FDA AUTHORIZES LYNCH REGENERATIVE MEDICINE'S IND FOR A PHASE IIB CLINICAL TRIAL FOR INJECTION OF RHPDGF-BB FOR TREATMENT OF INFRAORBITAL HOLLOWING

Reuters · 1d ago

Please log in to view news